Matinas biopharma announces positive in vivo safety data with its oral lnc-docetaxel formulation

Daily oral lnc-docetaxel, at a total administered dose of more than 8x greater than iv-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with iv-docetaxel

MTNB Ratings Summary

MTNB Quant Ranking